MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.490
-0.050 (-3.25%)
At close: Mar 9, 2026, 4:00 PM EDT
1.490
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:17 PM EDT
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,718,411
Market Cap
87.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Verrica Pharmaceuticals | 71 |
| PMV Pharmaceuticals | 47 |
| Pyxis Oncology | 44 |
| Vivani Medical | 37 |
| Cognition Therapeutics | 28 |
| iBio, Inc. | 20 |
| TuHURA Biosciences | 19 |
| Dogwood Therapeutics | 12 |
MAIA News
- 4 days ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 5 days ago - MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 6 days ago - MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 13 days ago - MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market - GlobeNewsWire
- 6 weeks ago - MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Announces $1.51 Million Private Placement - GlobeNewsWire
- 3 months ago - MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - GlobeNewsWire